Additionally, CHI3L1 may be associated with insulin resistance and obesity in the pathogenesis of NASH, and hepatic insulin sensitivity can be partially restored by parenteral given anti-Chi3L1 monotherapy (78). Here, INS is linked to obesity disorder.